Cytokines and psychopathology: lessons from interferon-alpha - PubMed

Review

Cytokines and psychopathology: lessons from interferon-alpha

Lucile Capuron et al. Biol Psychiatry. 2004.

Abstract

Interferon-alpha is a potent inducer of the cytokine network and is notorious for causing behavioral alterations. Studies on interferon-alpha-treated patients reveal at least two distinct syndromes: 1) a mood/cognitive syndrome that appears late during interferon-alpha therapy is responsive to antidepressants and is associated with activation of neuroendocrine pathways and altered serotonin metabolism; and 2) a neurovegetative syndrome characterized by psychomotor slowing, and fatigue that appears early during interferon-alpha treatment is antidepressant nonresponsive and may be mediated by alterations in basal ganglia dopamine metabolism. Findings from interferon-alpha may provide important clues regarding the pathophysiology and treatment of cytokine-induced behavioral changes in medically ill patients, while also potentially modeling the development of neuropsychiatric symptoms in patients without medical disorders.

Similar articles

• [Neuro-immune interactions in psychopathology with the example of interferon-alpha-induced depression].

  Capuron L, Dantzer R, Miller AH. Capuron L, et al. J Soc Biol. 2003;197(2):151-6. J Soc Biol. 2003. PMID: 12910630 Review. French.

• Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes.

  Licinio J, Kling MA, Hauser P. Licinio J, et al. Semin Oncol. 1998 Feb;25(1 Suppl 1):30-8. Semin Oncol. 1998. PMID: 9482538 Review.

• Mood and cognitive side effects of interferon-alpha therapy.

  Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Valentine AD, et al. Semin Oncol. 1998 Feb;25(1 Suppl 1):39-47. Semin Oncol. 1998. PMID: 9482539 Review.

• [Neuropsychiatric symptoms related to interferon alpha].

  Małyszczak K, Inglot M, Pawłowski T, Czarnecki M, Rymer W, Kiejna A. Małyszczak K, et al. Psychiatr Pol. 2006 Jul-Aug;40(4):787-97. Psychiatr Pol. 2006. PMID: 17068950 Review. Polish.

• Neuropsychiatric adverse effects of interferon-alpha: recognition and management.

  Raison CL, Demetrashvili M, Capuron L, Miller AH. Raison CL, et al. CNS Drugs. 2005;19(2):105-23. doi: 10.2165/00023210-200519020-00002. CNS Drugs. 2005. PMID: 15697325 Free PMC article. Review.

Cited by

• Immunoregulation and antidepressant effect of ketamine.

  Zhang N, Yao L, Wang P, Liu Z. Zhang N, et al. Transl Neurosci. 2021 May 26;12(1):218-236. doi: 10.1515/tnsci-2020-0167. eCollection 2021 Jan 1. Transl Neurosci. 2021. PMID: 34079622 Free PMC article. Review.

• Psychiatric clearance for patients started on interferon-alpha-based therapies.

  Lotrich FE. Lotrich FE. Am J Psychiatry. 2013 Jun;170(6):592-7. doi: 10.1176/appi.ajp.2013.12121572. Am J Psychiatry. 2013. PMID: 23732965 Free PMC article. No abstract available.

• Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

  Felger JC, Lotrich FE. Felger JC, et al. Neuroscience. 2013 Aug 29;246:199-229. doi: 10.1016/j.neuroscience.2013.04.060. Epub 2013 May 3. Neuroscience. 2013. PMID: 23644052 Free PMC article. Review.

• Microbes, Immunity, and Behavior: Psychoneuroimmunology Meets the Microbiome.

  Dinan TG, Cryan JF. Dinan TG, et al. Neuropsychopharmacology. 2017 Jan;42(1):178-192. doi: 10.1038/npp.2016.103. Epub 2016 Jun 20. Neuropsychopharmacology. 2017. PMID: 27319972 Free PMC article. Review.

• Cytokines sing the blues: inflammation and the pathogenesis of depression.

  Raison CL, Capuron L, Miller AH. Raison CL, et al. Trends Immunol. 2006 Jan;27(1):24-31. doi: 10.1016/j.it.2005.11.006. Epub 2005 Nov 28. Trends Immunol. 2006. PMID: 16316783 Free PMC article. Review.

Publication types

MeSH terms

Substances